$1.47
-0.04 (-2.65%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MBOT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, Squarepoint Ops LLC, +1 more) · FINRA short interest 13.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Assessment of Clin. Capabilities of LIBERTY® Endovascular Robotic System's Performance & Safety in Periph. Vasc. Interv.NCT06141694Effectiveness EndpointOpen-label · Treatment | Not applicable | Completed | Device: The LIBERTY® Robotic System | Peripheral Vascular Interventions | 20 | 2024-10-10actual | 2024-10-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19